LHC165X
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $27,815 | 3 | 0 |
| 2019 | $63,899 | 2 | 0 |
| 2018 | $47,335 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $139,049 | 8 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I IB OPEN LABEL MULTI CENTER DOSE ESCALATION AND DOSE EXPANSION STUDY OF THE SAFETY AND TOLERABILITY OF INTRA TUMORALLY ADMINISTERED LHC165 SINGLE AGENT AND IN COMBINATION WITH PDR001 IN PATIENTS WITH ADVANCED MALIGNANCIES | Novartis Pharmaceuticals Corporation | $139,049 | 0 |
Top Doctors Receiving Payments for LHC165X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $139,049 | 8 |
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $139,049
Product Information
- Type Drug
- Total Payments $139,049
- Total Doctors 0
- Transactions 8
About LHC165X
LHC165X is a drug associated with $139,049 in payments to 0 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2020. In 2020, $27,815 was paid across 3 transactions to 0 doctors.
The most common payment nature for LHC165X is "Unspecified" ($139,049, 100.0% of total).
LHC165X is associated with 1 research study, including "A PHASE I IB OPEN LABEL MULTI CENTER DOSE ESCALATION AND DOSE EXPANSION STUDY OF THE SAFETY AND TOLERABILITY OF INTRA TUMORALLY ADMINISTERED LHC165 SINGLE AGENT AND IN COMBINATION WITH PDR001 IN PATIENTS WITH ADVANCED MALIGNANCIES" ($139,049).